Evidence map›Paper›PMID 34294456›Full record

ArticleJournal francais d'ophtalmologie2021

The importance of tears stability in SARS-CoV-2 transmission: COVID-19 prevalance in dry eye patients.

O Agca, O Sayin

Open access · greenAbstract read
In one paragraph

Article in Journal francais d'ophtalmologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

O AgcaDepartmant of Ophthalmology, Konya City Hospital, Konya, Turkey. Electronic address: okanagca38@hotmail.com.
O SayinDepartmant of Ophthalmology, Konya City Hospital, Konya, Turkey.
Konya Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate whether dry eye disease (DED) is a risk factor for COVID-19.

methodIn this retrospective cohort study, patients who were diagnosed with DED by an ophthalmologist and whose Schirmer test was less than 5mm were identified. Patients who missed follow-up examinations, patients with malignancy, Human Immunodeficiency Virus patients and patients having undergone bone marrow transplantation were excluded. Among the DED patients, patients with positive SARS-CoV-2 PCR tests were identified on October 11, 2020. Subsequently, patients were divided into four age groups (25-49; 50-64; 65-79; and 80+). The COVID-19 prevalence per 100,000 people was determined for each age group, and risk analysis was performed by comparing this with the general population in Turkey.

resultsIn total, 10,023 DED patients were identified and included in the study. Among these, the PCR test was positive in 359 patients. The COVID-19 prevalence per 100,000 population in DED patients was calculated as 3581.7, while according to the Ministry of Health data, it was 524.7 in the general Turkish population. The odds ratio of DED patients versus the general population was 6.62 (P<0.001) (7.66 in the 25-49 group; 6.59 in the 50-64 group; 6.23 in the 65-79 group; and 7.24 in the 80+ age group).

conclusionsThe present study showed a high COVID-19 prevalence in DED patients compared to the general population. These findings support the concept that the ocular surface may be a gateway for SARS-CoV-2 and that the tear film is important part of the immune system.

Indexed as

COVID-19Dry Eye SyndromesHumansRetrospective StudiesSARS-CoV-2TearsCoronavirus infectionCOVID-19Dry eye diseaseDry eye patientsInfection par coronavirusMaladie des yeux secsPatients souffrant de sécheresse oculaireSARS-CoV-2SRAS-CoV-2

Identifiers

PMID34294456
PMCPMC8264519
OpenAlexW3181674527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.